Drug profile · INN
emtricitabine + rilpivirine + tenofovir alafenamide
ODEFSEY
emtricitabine + rilpivirine + tenofovir alafenamide (ODEFSEY) is an FDA-listed pharmaceutical active ingredient. Associated with Gilead Sciences Pty Limited.
TGA: approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — emtricitabine + rilpivirine + tenofovir alafenamide
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.81
Quick answer
emtricitabine + rilpivirine + tenofovir alafenamide (ODEFSEY) is an FDA-listed pharmaceutical active ingredient. Associated with Gilead Sciences Pty Limited.
Key facts
INN emtricitabine + rilpivirine + tenofovir alafenamide
Brand ODEFSEY
Originator Gilead Sciences Pty Limited
Approval history
| Authority | Status | Date |
|---|---|---|
| TGA | approved | — |
Frequently asked questions
What is emtricitabine + rilpivirine + tenofovir alafenamide?
emtricitabine + rilpivirine + tenofovir alafenamide (ODEFSEY) is an FDA-listed pharmaceutical active ingredient. Associated with Gilead Sciences Pty Limited.
What is the brand name for emtricitabine + rilpivirine + tenofovir alafenamide?
ODEFSEY is a marketed brand name for emtricitabine + rilpivirine + tenofovir alafenamide. Check FDA Drugs@FDA for the current US label holder and prescribing information.